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~£~~n Oncolgg
In any experimental protocol, the patient
comes first, the research objective second.

The primacy of patient welfare

Ethics

Ralph S. Freedman is
co-chairman of the M. D.
Anderson Surveillance
Committee

In 1966, the U.S. Public Health Service mandated
When physicians send patients to a research hospital,
the referring physicians and patients alike may experi- that all institutions receiving federal fonds must establish
ence ambivalent feelings. On the one hand, a research review boards to evaluate experimental protocols dehospital may offer the most sophisticated diagnostic signed for human subjects. This mandate has helped
techniques and therapies available. But on the other protect the rights of the patient, but it is a duty that
hand, the patient's relationship with the research physi- requires much time and emotional energy on the part of
cian can sometimes differ from his or her relationship the members of such boards. The constant balance
with the referring physician. The research physician's between the good of patients of tomorrow, who will
invitation to some patients to participate in experimenbenefit from today's research, and that ofthe patients of
tal protocols raises a singularly important question: what today, who often must choose between experimental
protocols and quality-of-life issues, is never-ending.
ensures the primacy of the patient's welfare?
Today, the responsibility for maintaining the primacy
At M. D. Anderson, this vigilance is the responsibility
of the patient's welfare is finnly that of research institu- of the Surveillance Committee, which reviews each
tions, but 30 years ago no
month about 20 proposfirm rules or guidelines
als. These proposals are
existed. In the absence of
usually for experimental
♦
such guidelines, patients
phase I protocols (in which
sometimes fell prey to unthe main objective is usu<'The physician-friend and the
ethical research practices.
ally to determine the maxiphysician-experimenter have different
Stanley J. Reiser, M.D.,
mum
tolerable dose of a
attitudes and interests, and when one
Ph.D., and Griff T. Ross
drug
or
combination of
doctor tries to combine the two parts
Professor of Humanities
drugs)
and
phase II protothere is a risk-quite a big risk
and Technology in Health
cols
(in
which
the main
sometimes-that the energy of the
Care at The University of
objective
is
to
determine
experimenter will prevail and that the
Texas Health Science Centhe response rate ofa single
patient will be deprived of the friend to
ter at Houston, observed:
agent
or combination of
whom he is absolutely entitled."
"In the era before the
agents
for which the dose
-T. F. Fox, Medicolegal Journal
1960s, the scientific comand
schedule
have already
(28:135, 1960)
munity lacked an institubeen determined by phase
♦
tional forum that continuI studies). This committee
allyreemphasized, through
is composed of 27 voting
a study of ethical quesmembers and seven nontions posed by actual research protocols, the ethical voting, or ex-officio, members. Membership includes
underpinnings of human research. Research abuses physicians from major clinical departments, which enwidely publicized in the 1960s, such as one involv- compass medical, surgical, and pediatric specialties, reping the injection of live cancer cells into 22 elderly resentatives from the Division of Nursing, the Social
cancer patients without adequately informing them, Service, the Department of Chaplaincy and Pastoral
and a heightened sensitivity to civil and human Education, and a former patient. In addition, members
rights in the United States became agents for also include people who are not employed by M. D.
change."
Anderson, such as lawyers, educators, and a representa-
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'-Informed consent
must be voluntary.
This is the key~
•
rive of an ethnic minority.
The Surveillance Committee is assisted in its review of
the scientific issues of clinical protocols by a peer review
committee (the prereview committee) that comprises
experts from many fields. Once the protocol has been
refined, it is submitted to the Surveillance Committee
for final approval. The scientific merit ofeach protocol is
independently evaluated by a minimum of two reviewers, whom the Surveillance Committee chairmen usually select from among physicians who have participated
in the prereview discussions and who therefore have a
good knowledge ofthe protocols. When this scientific
assessment is complete, one of these initial reviewers
presents the protocol to the entire committee, which
then considers not only its scientific merit but also
whether the protocol adequately protects the welfare of
the people it proposes to involve.
Experimental phase I and phase II therapies involve
complex interactions among medical investigators, pharmaceutical companies, the federal government, the
research institution, and the patient. Martin Raber,
MD., a chemotherapy specialist in the Department of
Medical Oncology who served on the Surveillance
Committee for five years, explained that although this
complexity of relations might seem to challenge the
primacy of the patient, it in fact serves the patient, for
what all parties share is a refusal to accept the incurability
ofdisease. According to Raber, many patients express an
interest in and are generally well informed about experimental therapies. "Patient interest is greater than the
availability of experimental therapies," said Raber.

Nonmedical factors often affect patient's decision
Patients such as these know what the want and
actively seek it out. Some patients, however, would not
choose to participate in a study unless, or even if, asked
by their attending physician. For them, potential benefits of experimental therapy may not outweigh the
compromises they would have to make in other areas of
their lives. As committee co-chairman Ralph S. Freedman, M.D ., Ph.D., pointed out, many patients live long
distances from the hospital, which means spending
much time and money on transportation. In addition, a
patient often must decide whether he or she can continue to hold a job while undergoing therapy and ifnot,
what the emotional and economic consequences for
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both the patient and the family might be. Some terminally ill patients would rather spend their last months at
home with their families than in a hospital receiving
experimental therapy. Any patient who may teeter on
the edge of giving his or her consent is especially
vulnerable. No matter what their enthusiasm for a new
protocol, physicians should respect a patient's choice to
refuse experimental therapy based on nonmedical considerations.

To be voluntary, consent must be based on
complete information
Besides posing emotional and economic concerns,
experimental therapies also entail varying degrees of
physical risk, and it is one ofthe Surveillance Committee's
most important duties to ensure that protocols sufficiently provide for obtaining the patient's informed
consent. The principal investigator or physician is responsible for gaining the patient's informed consent
and documenting it with a written form that the Surveillance Committee must approve. Freedman emphasized, "Informed consent must be voluntary. This is the
key." To promote genuine voluntariness, documents of
informed consent must set forth the purpose of the
therapy, describe its procedures, risks, side effects, and
discomforts, and indicate potential benefits. In addition,
the document must include a description of alternative
procedures or treatments and their risks and benefits.
Only when an investigator has communicated these
details to the patient, allowing time for the patient to ask
questions and think, is the principle of patient
voluntariness respected.

Although this process of informed consent is adequate in theory, Freedman acknowledged that the
practice ofsecuring a patient's informed consent may be
problematic. For example, despite the specificity of
written documentation about the therapeutic regimen
that the principal investigator must provide to patients,
language that is medically accurate is not necessarily
readily understandable to the patient.
Another problem is that the process of informed
consent relies greatly upon the principal investigator's or
physician's oral communication with a patient. Without
necessarily being aware of it, a physician might subtly
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-'Deviations from the preferred
treatment for a specific disease
require review"
•

•

•

pressure the patient. Freedman said that, to address this
problem, some medical departments at M. D. Anderson have begun to counsel physicians about oral communication with patients.
Stanley Reiser, an extramural member of the Surveillance Committee, concurs with Freedman that the
process of informed consent is crucially important and
raises problems that need more attention. "What happens after informed consent is obtained?" asks Reiser.
"Does such consent for a proposed therapy raise false
hopes?" Similarly, he thinks that assessments of a
patient's and the family's observations on their actual
experience oftherapy compared with their expectations
prior to therapywould provide useful information about
the process of informed consent. Such questions not
only warrant study by principal investigators, Reiser
believes, but they also merit research by medical students in their courses in medical ethics, an area of study
that both Reiser and Freedman find to be contributing
significantly to the increased ethical awareness of medical investigators and practitioners.

Financial interest in the protocol is an important
issue
In addition to ethical problems possibly posed during
oral communication in the course of acquiring informed consent, another ethical problem is whether
review boards should assess a principal investigator's
financial relationship to a pharmaceutical company.
According to Reiser, interest in having physicians reveal
their economic arrangements with pharmaceutical
companies arises out of concern for how such arrangements affect both the scientific objectivity ofa therapeutic regimen and the ethical treatment of patients. Presently, no federal or institutional regulations mandate
scrutinizing investigators' economic relations with a
pharmaceutical company, but any protocol reviewer or
any committee member may raise the issue for consideration, Freedman said.
A final question remains: What if, even after thorough
review and conscientious assessment, a research idea
proves wrong? Say 20 patients have been enrolled in a
three-year study that is designed to enroll at least a 100,
but six months into the study the data are overwhelmingly negative. Should the study continue, thus subjecting more patients to a protocol that increasingly seems

•

•

•

ineffective? To guard against this dilemma, the Surveillance Committee sometimes requests an early review of
data after a predetermined number of patients have
been entered on a protocol; this number could be six or
fewer. Additionally, the committee has an innovative
review process for pilot protocols that test the validity of
research ideas, Freedman said. The pilot studies are
implemented for therapies that do not put patients at
any greater risk than they would experience under
current practice for a particular disease; however, in
contrast to most protocols, pilot studies include a maximum of 15 patients and fewer than three investigators.
If data from these pilot studies prove promising, then
more comprehensive studies can be planned, but ifnot,
then the project can be terminated or modified, thus
ensuring that additional patients are not enrolled in a
protocol that shows no promise.

Research must show a potential for innovation
Ethical review committees like the Surveillance Committee necessarily educate reviewers and investigators
directly involved in its deliberations. According to Freedman, this educational process inheres in rigorously
addressing a single, crucial question: what constitutes
research? "The Belmont Report: Ethical Principles and
Guidelines for the Protection of Human Subjects of
Research," which a presidential commission issued in
1978 to provide a basis for federal policy on research
involving people, gave the question ofwhat constitutes
research its first official articulation. In contrast to "practice," which "refers to interventions that are designed
solely to enhance the well-being ofan individual patient
or client and that have a reasonable expectation of
success," "research" refers to "an activity designed to
test a hypothesis, permit conclusions to be drawn, and
thereby to develop or contribute to generalizable knowledge (expressed, for example, in theories, principles, and
statements ofrelationships)" and "is usually described in
a formal protocol that sets forth an objective and a set of
procedures designed to reach that objective." Although
not just any alteration of standard practice renders a
treatment experimental, "radically new procedures ...
should, however, be made the object offormal research
at an early stage in order to determine whether they are
safe and effective." Accordingly, it is the task of review
committees like M. D. Anderson's Surveillance Comcontinued on page 7
page 3
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Prevention and control will depend on
understanding brain activity.

Cognitive deficits in survivors
of childhood cancers

Treatment Update

Bartlett D. Moore Ill is
an assistant professor of
pediatrics in the
Department of
Pediatrics.
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The good news is that more and more children with
cancer are surviving their disease. Twenty years ago, the
five-year survival rate for children with cancer was about
50%; in 1990, it was projected to be about 80%. The
bad news is that some ofthese survivors may be suffering
long-term or permanent adverse effects, not of their
cancers, but of the very treatments that are saving their
lives. This is not a new idea; physicians and educators
working with these survivors have long noticed their
unusually high incidence of cognitive and intellectual
impairments, such as learning disabilities, attention deficits, poor memory, slower-than-normal task performance, and perception problems. These cognitive difficulties have often been attributed to psychosocial factors
associated with treatment of a chronic, life-threatening
illness. However, these sequelae do not appear in all
survivors, and often their appearance is delayed from a
few to five years, leading some researchers to attribute
them instead to gradual pathologic changes in the brain.
The perplexing problem of identifying the causes and
predicting the occurrence of these cognitive deficits has
been undertaken by researchers at The University of
Texas M. D. Anderson Cancer Center.
Bartlett D. Moore III, Ph.D., and his colleagues in
the Department of Pediatrics are studying both survivors and children who are being treated for cancer in
hopes of learning what factors contribute to these
cognitive deficits. Moore, a neuropsychologist, is an
assistant professor ofpediatrics who specializes in assessing children's intellectual and cognitive abilities. He is
extending the neuropsychological research effort in the
department, initiated 10 years ago by his colleague
Donna Copeland, Ph.D., into the area ofneurophysiology, the study of brain function, through the use of
electrophysiological measures. Copeland described it
this way: "Neuropsychologymeasures behavior, whereas
CT [computed tomography] and MRI [magnetic resonance imaging] measure the structure and anatomy of
the brain. Dr. Moore's electrophysiological tests provide the bridge between the two. They tell us about the
'hard wiring' of the brain. His work will allow us to
correlate structural and cognitive development." Moore
used a similar metaphor when he compared cognitive
development in these survivors to computer software
that does not run properly because of problems in the
computer hardware; his work aims to find the underly-

ing problem in the "hardware" of the brain. Using
microcomputer technology, Moore conducts electrophysiological tests to study how brain activity in the
cancer survivors with cognitive problems differs from
that in the survivors who do not suffer these problems.

Treatments implicated in long-term deficits
Supported by grants from the American Cancer
Society, Moore is studying survivors of different types of
childhood cancer (defined as any cancer diagnosed
before the patient is 16 years old) and the effects of
different kinds of treatments. Subjects for the study are
recruited from the M. D. Anderson Long-Term Follow-Up Clinic, which is directed by Hubert L. Ried,
MD. Treatment of children with cancer depends on a
number offactors, including the type and location ofthe
cancer and the child's age. Treatments involving the
central nervous system (CNS) are thought by many
observers to be causal factors in these long-term cognitive effects. They suggest that the white matter of the
brain, the myelin sheath that protects the nerve cells and
increases the speed of brain processing, may be damaged by these treatments. Moore said, ''we know that
some of these long-term survivors have cognitive and
intellectual deficits. Other researchers have studied the
physical changes in the brains of these survivors. We're
looking at brain function as a link between the cognitive
deficits and the treatments these children receive."
Moore's study addresses the hypothesis that intensive
CNS therapy that includes cranial radiation therapy
(CRT) damages this white matter, disrupting normal
patterns of cortical connectivity and slowing brain
activity essential to normal cognitive functioning.
CRT became one focus of Moore's study because it
has been very widely used: in the past it was used
prophylactically in most children with leukemia to prevent CNS metastases. It is still used to treat some
patients who relapse and is also used extensively in
children with brain tumors.
Moore studied three groups: those who had rec;eived
no CNS therapy, those who had received systemic
chemotherapy with or without CNS chemotherapy,
and those who had received intensive CNS therapy,
including chemotherapy and CRT. The groups received identical batteries of electrophysiological tests.
"We're examining whether chemotherapy and radia-
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ti.on therapy have any long-term physiological effects,"
Moore said. "There seems to be a consensus that
therapies that include CRT do have some cognitive
effects whose onset m ay be delayed for several years after
therapy. The complication with this type ofstudy is that
very few patients get only one kind of treatment. One
third of the subjects in this study received both CNS
chemotherapy and radiation therapy, and there's evidence that the two have a synergistic effect. Some
researchers are showing cognitive deficits in children
after CNS chemotherapy [without CRT], but we haven't
in our studies." What they have seen is corroboration of
their hypothesis that intensive CNS therapies that include CRT, when used in children, can cause these
deficits. Moore saw a significant performance deficit in
the group of long-term survivors whose treatment
included both CRT and CNS chemotherapy. The
groups treated with only chemotherapy (systemic, CNS,
or both) were within the average range of functioning.

Electrophysiological tests reveal deficits
Electrophysiological tests comprise a variety of techniques for detennining the speed and organization of
CNS processing, that is, how well the CNS is functioning. Most of the tests are performed by Bernadette
Levy, a research assistant in Moore's laboratory, and
include spectral analysis of electroencephalograms;
brainstem, sensory, and cortical evoked J?Otentials; and
motor reaction time and dichoti.c listening tests. Most
are measured on a microcomputer-based system: while
electrodes attached to the scalp measure brain activity,
· the subject responds to automated stimuli, and the brain
responses are amplified, digitized, recorded, and analyzed by the computer. When brainstem and simple
sensory evoked potentials were recorded under resting
conditions, there were no differences among the treatment groups; the group that received intensive therapy
including combined CNS chemotherapy and CRT
showed no impairment. However, when cortical evoked
potentials were m easured while the subject was involved
in a mental task, definite differences were apparent
among the treatment groups: those who had received
no CNS therapy had the fastest cortical reactivity, and
those who had received the most intensive CNS therapy,
including CNS chemotherapy and CRT, had the slowest. Those who had received CNS chemotherapy alone
had intermediate values. Asimilar gradient was found in
the responses to a test of motor reaction time in which
the subjects were required to push a key as quickly as
possible in response to a visual stimulus after being
presented with a warning stimulus several seconds earlier. In one condition, the interval between the stimuli
was constant (4 seconds), whereas in another the inter-

val varied randomly ( 1 to 6 seconds). Those who had
not received intensive CNS therapy were able to use
their foreknowledge of the constant interval to increase
their reaction times by about 20% over those in the
random condition. The patients who received intensive
CNS therapy, however, were not able to benefit from
this knowledge to improve their speeds over patient in
the random condition.
Many of these electrophysiological measures correlate with cognitive ability, suggesting that they can be
used to detect or predict cognitive deficits associated
with cancer treatment. Moore believes that since evoked
potentials measure the speed of information processing
in the brain, they can be used to measure reductions in
this speed in impaired patients, even if the damage
to the brain cannot be detected on CT and MRI
images. He further believes that his results support
the idea that CRT and, to a lesser degree, CNS
chemotherapy damage the white matter tracts of the
brain, resulting in slowing and disorganization of cortical functions necessary for efficient cognitive activity.

First step to prevention
Moore's research is helping explain the physiological
basis of cognitive deficits following cancer treatment,
providing a rationale for designing new and effective
therapies that minimize long-term cognitive effects. He
is now planning to study children being treated for
cancer to identify patterns or other clues ofneurological
damage that may allow prediction of future cognitive
deficits. The ability to detect the damage as it is happening will allow clinicians to alter treatments and, Moore
and his colleagues hope, either prevent the deficits or
reduce their severity. It is also important to learn more
about the nature of these deficits so that the survivors
who suffer them can be successfully rehabilitated.
In light ofthese discoveries, what is the future ofthese
intensive CNS therapies that cause the deficits? Moore
was quick to note that a medical cure is necessary before
the child can resume normal life, and that freedom from
these deficits is irrelevant ifthe child does not survive the
cancer. Neither he nor other researchers in the field
advocate stopping these treatments. He does note that
intensive CNS treatments are avoided in very young
children at M. D. Anderson, and that, whenever possible, delaying these treatments until the CNS has
matured can prevent or lessen their hannful effects . ■
Physicians who desire additional information may
write Bartlett D. Moore III, Ph.D., The Department
of Pediatrics, Box 87, The University of Texas M. D .
Anderson Cancer Center, 1515 Holcombe Blvd.,
Houston, Texas 77030, or call (713) 794-4467.
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Doubling Time
continued from page 8
response to therapy, particularly to radiation.
"The first thing we set out to do-and this was based
on what I did with my colleagues in England before I
came here in 1987- was to establish whether there is a
spectrum of underlying potential doubling times in cell
populations, even in a seemingly homogeneous population of tumors," Terry said.

Potential doubling time varies widely
In preliminary studies ofabout 200 patients who had
either head and neck cancer or rectal cancer, ''we have
found an enormous range in this parameter, irrespective
of how quickly the tumor lump was growing. Tumor
cells can be growing and proliferating very quickly, even
though the lump is not, since existing cells can be dying
just as quickly as new cells are proliferating," Terry said.
"For tumors that have fast-growing subpopulations
with short potential doubling times, it might make sense
to accelerate treatment; rather than give conventional
radiotherapy of some 72 fractions in seven weeks, you
might want to get the whole treatment in five weeks, for
example. But it's a trade-off. Accelerated treatment
means a greater risk of normal tissue damage, and of
course the whole balancing act is to sterilize the clonogenic
cells in the tumor while sparing normal tissues."
After the range in potential doubling times was
confirmed, the next step was to obtain data on tumor
response, local tumor control, and patient survival. In a
small cohort of rectal cancer patients, Terry and his
clinical colleagues have already noted a correlation between tumor response and potential doubling time.
Patients with fast-growing tumors (which have short
potential doubling times) do worse than patients with
slow-growing tumors (which have long potential doubling times). Within a year, they hope to have specific
d~ta on local control and survival, not only for rectal
cancer patients but also for those with head and neck
cancer. "Our studies of both tumors are maturing at
the the same time," Terry said. "In head and neck
studies, about 65 of 100 cases will have had at least
two years of follow- up."
Correlations of potential doubling time with patient
survival would be encouraging, but not the final word.
"We haven't yet stuck our finger in the fire and prescribed treatment based on potential doubling time. We
haven't yet said, 'Okay, because your tumor has such
and such a doubling time, we think you should have
accelerated radiotherapy and more intense chemotherapy,"' Terry explained. "There's still a panoply of
factors that need to be considered, not only the surgical
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staging and other clinical parameters but also, perhaps,
the intrinsic radiosensitivity of the tumor."

Obtaining an accurate prognosis depends on
sophisticated models
Sorting out those factors will require sophisticated
experimental models. In the realm of mouse tumor
systems, such models already exist, but for human
tumors the task has been more difficult. In mouse
models, multiple samples can be taken both from
within individuals and from across a large homogeneous population. Any assumptions about prognostic
parameters can therefore be verified by the use of such
"multiple replicates." But for humans, it is essential that
any type ofprognostic test be reliable using one surgical
sample or biopsy. Development b f such models, which
has already begun at M. D. Anderson Cancer Center,
is "a very interactive project" involving four departments, Terry said. Some ofTerry's collaborators are R.
Allen White, Ph.D., Department ofBiomathematics,
who conceptualizes mathematical models that are then
tested in cell culture or mouse systems; William A.
Brock, Ph.D., Department of Experimental Radiotherapy, who is currently devising studies to assess
patient and tumor radiosensitivity; and Lester J. Peters,
M.D ., head of the Division of Radiotherapy. Peters,
together with his colleagues Hehnuth Goepfert, M.D .,
chairman, Department of Head and Neck Surgery,
and David M. Ota, M.D ., deputy chairman ofD epartment ofGeneral Surgery, directs the clinical arms ofthe
studies. In addition, cooperation with the Division of
Pathology is vital for obtaining specimens in a timely
fashion.

Complicated logistics necessitates clockwork coordination
At this stage in Terry's studies, his collaboration
with his clinical colleagues is especially important,
for the data they are gathering now, as mentioned
above, will determine whether potential doubling
time correlates with local tumor control and patient
survival. The task, however, is logistically daunting .
The study population extends across two services;
furthermore, some patients may undergo one of
several possible types of biopsy, whereas others m ay
undergo one ofseveral types ofsurgery. Many ofthese
procedures are performed by different specialists in
different locations ofthe hospital. For example, surgery
patients are often perfused with bromodeoxyuridine
by the anesthesiologist, whereas biopsy patients may be
perfused in the ambulatory infusion clinic. The result:
many people in a variety of departments need to know
precisely what to do and when to do it.
"It's a big deal when we've got patients undergoing
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the procedure. We have fingers all over the place making
sure everyone knows what is happening," Terry said.
Since the accuracy ofthe bromodeo:xyuridine perfusion
technique is highly time dependent, "we need to know
precisely when the patient is perfused and when the
biopsy or specimen was taken."
M. D. Anderson collaborates with European research facility
Such collaboration requires extensive dialogue within
M. D. Anderson, but Terry is also in another dialogue of
sorts with other research facilities. Three other institutions are researching aspects ofpotential doubling time
as determined by bromodeoxyuridine perfusion. All
share a desire to standardize the methodological and
analytical techniques of the bromodeo:xyuridine techniques, but they are going about it differently.
"We've published a lot of data on cell kinetic theory
and analytical models. The University of Wisconsin
group is working ve1y hard along the same lines we are,
trying to gain fundamental insight into cell kinetics,"
Terry said. "The group at the Gray Laboratory (London) is collecting an enormous spread of clinical data,
but they're not focusing on theory. Adrian Begg's
group at the Netherlands Cancer Institute is somewhere
in between. Begg has great insight into the analytical

methodology, which he is sharing with us, but his group
isn't building the models."
Almost certainly, the academic aspect of this type of
research will proceed as it has for the past 40 years or so,
with radiation biologists like Terry elucidating the fundamental questions of cell kinetics. The unresolved
question, though, is the utility of such research for
clinical use. "Ifall we're doing is measuring a parameter
that is closely correlated with other variables such as
staging or something like that, then our technique
probably won't be useful," he said. "It's quite an
investment in lab time and machine time. But if-and
this is something that Allen White and I are particularly
concerned about-if we can create a reliable, independent prognostic technique, then it might be possible to
make it relatively inexpensive. The question is, does the
technique give any benefit to a significant cohort of
patients? That's where we are right now, and that's what
we hope our clinical studies will show. The next two
years should be very exciting." ■
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Patient W elfare
continued from page 3
mittee to ensure that "a major innovation be incorporated into a formal research project," for "the general
rule is that if there is any element of research in an
activity, that activity should undergo review for the
protection of human subjects."
Freedman emphasized the necessity of maintaining
the crucial distinction between practice and research
and thinks that relentlessly pursuing the question, ''What
constitutes research?" rightfully compels research physicians to continuously assess their motivations. "Taking
the best care of patients means that a physician sometimes has to be innovative," Freedman said, "and a
research protocol may offer patients an opportunity to
receive the best therapy. Treating breast cancer with
taxol is an example ofsuch an opportunity." Yet Freedman cautioned that "physicians must know that deviations from the preferred treatment for a specific disease
require review." Intellectual excitement over possible
discovery and publication of a research report should
never take primacy over patient welfare. The single most
important educational role of the process of ethical

review, Freedman thinks, is that it exists to force the
question of motives.
Reiser, too, affinned the educational value of the
review process but believes that the educational role
warrants expansion. He pointed out that since the work
load of reviewing proposed protocols prohibits most
review committees as they are presently structured from
assuming a more active part in education, a review
committee might create a separate arm to realize more
ofits educational potential. ■
Physicians who desire additional information may
write Ralph S. Freedman, M.D., Ph.D., Department
of Gynecology, Box 67, or Martin Raber, M.D.,
Department of Medical Oncology, Box 92, The
University of Texas M . D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, Texas 77030;
or Stanley J. Reiser, M.D., Ph.D., Office of the
Program on Humanities and Technology in Health
Care, The University of Texas Health Science Center,
P.O. Box 20708, Houston, Texas 77225 . Physicians
may also call Drs. Feedman, Raber, and Reiser at (713)
792-2770 (Freedman), (713) 792-7765 (Raber), or
(713) 792-5140 (Reiser).

David M. Gershenson, M.D.
Frankie A. Holmes, M.D.
Raymond E. Meyn, Jr., Ph.D.
William Plunkett, Ph.D.
Tyvin A. Rich, M.D.
S. Eva Singletary, M.D.
Michael J. Wargovich, Ph.D.
Published quarterly by the
Department of Scientific
Publications, Division of Academic
Affairs, The University of Texas
M. D. Anderson Cancer Center,
1515 Holcombe Boulevard,
Houston, Texas 77030.
Made possible by a gift from
the late Mrs. Harry C. Wiess
and by grants from The University
Cancer Foundation.

page 7

MD Anderson Oncolog
Scientific Publications, Box 234
M . D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, Texas 77030

Address correction requested

Inside
Ethics of experimentation
Cogni tve deficits after herapy
Tumo biology and prognosis

Nonprofit Org .
U. S. Postage
PAID
Permit No. 1
Austin, Texas

Oncolog
TI-£ LNMRSllY OFTEX'6

MDAN)ERSON

CANCERCENrER

Potential doubling time of tumors may
be the key to accurate prognosis,
appropriate treatment
Lab to Clinic

Nicholas H. A. Terry is an
assistant professor in
the Department of
Experimental
Radiotherapy

"I've been known to make a bloody nuisance of
myself, but when we have a surgery patient scheduled
for bromodeoxyuridine perfusion, we're very jealous of
making sure everything works," said icholas H. A.
Teny, Ph.D., an assistant professor in the Department
of Experimental Radiotherapy at The University of
Texas M. D. Anderson Cancer Center.
The operating room is not the typical habitat of a
radiation biologist like Teny, who has devoted almost a
decade to analyzing cell cycle kinetics in mice and in cell
culture. His location of choice is the research wing, in a
room that he shares with a flow cytometer. But Terry's
current basic research requires occasional forays into the
world of the surgeon. The prognostic capabilities of his
bromodeoxyuridine perfusion technique have already
proved promising in experimental systems. If current
human studies progress as Terry hopes, the test may be
useful in determining the most effective radiotherapy for
patients with certain tumors.

Tumor growth rate may be prognostic
The key aspect of the bromodeoxyuridine technique
is that it allows one to estimate the growth rate of cells
within tumors. Patients are first infused with nontoxic
levels of bromodeoxyuridine. Several hours later, a
surgical biopsy is taken and manipulated such that total
DNA and bromodeoxyuridine-labeled DNA can be
visualized and quantitated using a flow cytometer, a
device that measures cellular constitutents based on the
amount of incorporated fluorochromes. Because
bromodeoxyuridine binds only to cells in the DNA
synthesis (S) phase, it can be used to distinguish S-phase
cells from those in other phases ofthe cell cycle. Why are
S-phase cells important? By knowing the fraction ofSphase cells in the total population and their rate of
progression, one can estimate the tin1e it would take,
theoretically, for the population to double. This parameter is called the "tumor potential doubling time," and
Terry expects that it may correlate with a tumor's
continued on page 6

